Latest news with #BoehringerIngelheim
BBC News
19 hours ago
- Business
- BBC News
German pharma firm signs deal worth up to $1bn with QUB spin out
A medical technology company founded by Queen's University academics has signed a licensing agreement with a major pharmaceutical firm which could ultimately be worth up to $1bn (£744.1m).Re-Vana Therapeutics, which was set up in 2016, develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of care for major benefit of its technology is that it reduces the number of eye injections patients require making them more likely to follow their Ingelheim, a German pharmaceutical firm, is licensing the drug delivery system to combine it with its eye medications. The German firm will take responsibility for regulatory approvals and global commercialization of products developed using the Re-Vana Ingelheim said the deal involves "upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1bn for the initial three targets, in addition to royalty payments on net sales".Re-Vana was founded by Professor Raj Thakur and Professor David Jones with investors including Qubis, the commercialisation arm of Queen's company is now based in the US but still has its research base in O'Rourke, Re-Vana's Chief Executive Officer, said the collaboration with Boehringer Ingelheim is a "transformational moment".The deal has also been welcomed by NI Secretary of State Hillary Benn who said it "represents a huge vote of confidence in Northern Ireland's innovation and skills".
Yahoo
21 hours ago
- Business
- Yahoo
Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] – Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. Globally, millions of people living with eye health conditions face a progressive decline in their independence and connection to the world due to vision loss. With its diverse pipeline in eye health, which includes four assets in Phase II, Boehringer Ingelheim is committed to preserving the retina, protecting people's way of life and preventing vision loss. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vana's drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections. Lowering the treatment burden could lead to higher treatment compliance, and potentially result in better therapeutic outcomes. Boehringer Ingelheim will explore combining this technology with its unique pipeline in eye health. 'We're looking forward to team up with Re-Vana to push the boundaries of what's possible in eye health,' said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. 'Together, we want to tackle the limits of today's treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.' 'The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,' said Michael O'Rourke, Re-Vana Chief Executive Officer. 'By combining our extended-release platform with Boehringer Ingelheim's world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.' Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana's feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at (Global) or (UK). About Re-Vana Therapeutics Re-Vana Therapeutics Ltd, founded in 2016 as a spin-out from Queen's University Belfast, is an ocular therapeutics and innovative ocular drug delivery company based in Belfast, Northern Ireland, and a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida. Re-Vana is venture backed with leading US Ophthalmic investors including Visionary Ventures, ExSight Ventures, InFocus Capital Partners and UK investors including QUBIS, TechStart Ventures, Invest Northern Ireland and Clarendon Fund Managers. Re-Vana is currently raising a Series B round for their sustained release anti-VEGF asset. Learn more at Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. Media Contacts Boehringer Ingelheim: Dr. Reinhard MalinBoehringer Ingelheim Corporate Center GmbH Innovation Unit/Bio Comms, Corp. Affairs Media + PR press@ Linda RuckelBoehringer IngelheimInnovation Unit Re-Vana: Michele Gray Gray Communications, LLCMichele@ 917 449 9250Sign in to access your portfolio
Hamilton Spectator
5 days ago
- Business
- Hamilton Spectator
First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported positive growth in the first half of 2025, with group net sales growing by 6.3%* to EUR 14.0 billion. This performance was driven by strong demand for key products in Human Pharma, namely JARDIANCE® with EUR 4.3 billion and OFEV® with EUR 2.0 billion, which continue to make a meaningful difference for patients worldwide. Building on this momentum, the company is advancing its late-stage pipeline with several therapies nearing regulatory approval. Among these are zongertinib for HER2-mutant lung cancer and nerandomilast for pulmonary fibrosis, both of which recently delivered positive pivotal results and are progressing towards potential launches in the second half of 2025. 'At Boehringer Ingelheim, our commitment to transforming lives for generations is more than a mission — it's a responsibility we carry forward every day. Therapies like JARDIANCE® and OFEV® continue to make a real difference to patients — they exemplify what's possible when true innovation addresses unmet medical needs,' said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma. 'At the same time, we're making strong progress across our pipeline — from obesity to liver and kidney health — with the goal of redefining standards of care. As we prepare for the potential launches of zongertinib and nerandomilast later this year, we remain focused on delivering meaningful solutions. We understand the urgency behind every patient's need, and we're acting with speed and purpose to meet it.' Frank Hübler, Member of the Board of Managing Directors responsible for Finance, added: 'In a volatile environment, we are delivering according to plan, with robust sales performance across our portfolio in human and animal health. As we prepare for major launches, we are investing more than ever – focusing on speed, scale, and impact to ensure we are ready to deliver innovative therapies to change the course of serious diseases. Beyond the excitement of new launches, we also see substantial growth potential in our established products, particularly with JARDIANCE®, which continue to make a meaningful difference for patients worldwide.' Human Pharma In the first half of 2025, Boehringer Ingelheim's Human Pharma business grew 5.7%* reaching EUR 11.3 billion in net sales. Growth was driven by solid global demand for key products, including EUR 4.3 billion in sales from JARDIANCE®, the treatment of chronic kidney diseases, type 2 diabetes and heart failure, and EUR 2.0 billion in sales from OFEV®, which is used to treat idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases. Boehringer Ingelheim's human pharma pipeline is strong, with over ten new Phase II and III trials starting in the next 12 to 18 months across our multiple therapeutic areas. These could lead to major product launches over the next five years, offering the potential to transform millions of lives. U.S. launches for zongertinib and nerandomilast are expected in the second half of 2025, pending FDA approval. Zongertinib, a targeted therapy for HER2-mutant advanced non-small cell lung cancer (NSCLC), showed durable response and clinically meaningful results in previously treated patients, with more than 70% of patients experiencing a tumor response. It is under regulatory review in U.S., Japan and China and being studied as a first-line treatment in a global Phase III trial. If approved, it would become the first orally administered targeted treatment for previously treated HER2-mutated lung cancer patients. Nerandomilast, a potential therapy for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), significantly slowed lung-function decline in the two FIBRONEER™ Phase III trials. It was well tolerated, with discontinuation rates comparable to placebo. Regulatory submissions have been made in the U.S., EU, China and Japan. The company also launched a Phase III trial for our DPP1/CatC inhibitor verducatib (BI 1291583) to evaluate its potential in treating bronchiectasis. Verducatib received FDA breakthrough therapy designation in 2024. In cardiovascular, renal, and metabolic (CRM) diseases, Boehringer Ingelheim started two new Phase III trials under the ongoing EASi trial program. In these trials, the company is investigating the potential benefits of an aldosterone synthase inhibitor/SGLT2i therapy in people with chronic heart failure and for cardiovascular risk reduction in people with type 2 diabetes, high blood pressure and cardiovascular disease. To support future launches and continued growth, the company is continuing to strengthen its global supply network. A key milestone is the EUR 300 million investment in its Yamagata site in Japan, with the opening of a new production unit, infrastructure measures and groundbreaking for an additional facility began in June. This expansion will position Japan as a critical production hub for the Asia and Oceania regions. At the same time Boehringer continues to strengthen its local production network in the USA, building on existing partnerships. Animal Health In the first six months of 2025, Boehringer Ingelheim's Animal Health Business delivered strong growth, with net sales increasing by 7.6%* to EUR 2.6 billion. This performance was driven by continued momentum in the parasiticide portfolio, particularly the NEXGARD® brand, which grew by 7.9%*. A key growth driver in Europe was BULTAVO 3™, a newly launched vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first vaccine to prevent both clinical signs and mortality from BTV-3 and has been licensed in several European countries. The company also expanded its vaccine portfolio with the launch of VAXXITEK® HVT+IBD+H5, a trivalent poultry vaccine, offering protection against Marek's disease, Infectious Bursal Disease, and H5 avian influenza in a single shot. It was first introduced in Egypt in early 2025 and is designed for administration directly at the hatchery, providing early protection for chicks. In the companion animal segment, Boehringer Ingelheim entered a strategic digital health collaboration with Eko Health to improve early detection of heart disease in dogs. The partnership combines Boehringer's expertise in canine cardiology with Eko's AI-powered stethoscope technology, aiming to launch a dedicated mobile app for veterinarians in 2026. Outlook As Boehringer Ingelheim enters the second half of 2025, the company is well-positioned to build on its first-half year performance and expects a positive year-on-year increase in net sales. With major product launches, a robust pipeline, and strategic investments in R&D and manufacturing, Boehringer Ingelheim is set to expand its global impact and bring innovative health solutions to more patients and animals worldwide. Visit our half-year financial highlights page HERE . * on a comparable basis (adjusted for currency and other effects) Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at . Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Local Spain
19-07-2025
- Business
- Local Spain
Why Vienna is Europe's hidden gem for life sciences
With its impressive architecture and coffee house-lined streets, Vienna is a city like no other. Situated on the banks of the Danube, it is steeped in history and has long been a cultural capital of Europe. These days, however, the city is just as defined by its future as its past. Thanks to forward-thinking research centres, top-ranked universities and an expanding base of life sciences companies, Vienna is a rising powerhouse in biotech, medtech, and pharmaceutical research. Vienna is the European leader in life sciences 'Life sciences are one of Vienna's key drivers of innovation,' said Dominic Weiss, Managing Director of the Vienna Business Agency, which supports the ecosystem through funding programs, location scouting and other expert support, such as immigration advice. 'Over many years, life sciences companies ranging from international pharmaceutical giants to startups working on the bleeding edge of technology have repeatedly chosen to move to, invest and expand in this city, collaborating with local universities to create an internationally competitive hub that produces game-changing therapies, devices and diagnostic tools.' The sector is made up of over 750 organisations, generating about €22.7 billion a year. The vast majority of revenue – just over 80 percent – stems from the biotech and pharmaceutical sectors alone. More than 49,000 people currently work in life sciences – and the numbers are rising as ever more international experts are drawn into the ecosystem. 'Part of what makes Vienna an attractive location for life science companies is that the city combines an excellent research landscape and university talent pool with a great deal of attractiveness for top international researchers and executives,' Weiss added. 'Moving to Vienna is not a hard sell.' Combining top-ranked livability, affordability and a strong work-life balance, it's no wonder that international researchers and entrepreneurs are choosing to call Vienna home. In fact, around 40 percent of the Austrian capital's two million residents were born abroad, giving the city a truly diverse feel. Thriving life sciences hub Some of the world's top life science firms – including pharma giants Takeda, Boehringer Ingelheim and Novartis – have offices in Vienna. Meanwhile, cutting-edge research institutions working on everything from tissue regeneration and cancer therapies to prosthetics are well established in the Austrian capital. What really sets Vienna apart is how closely connected this ecosystem is. Research labs, clinical research facilities and companies are often within walking distance of each other. 'This spatial density creates collaboration opportunities and translational potential that researchers find on par with top global locations,' says Dr Michael Stampfer, Managing Director of the Vienna Science and Technology Fund (WWTF). Groundbreaking research is underway in facilities such as the Vienna BioCenter, which has more than 2,000 scientists covering fields like cancer biology, immunology, and RNA therapeutics. One standout project is US biochemist Elly Tanaka's work in regeneration biology. By studying animals that can regrow limbs and tissues, Tanaka's lab at the IMP is researching potential treatments for human diseases. And the city isn't slowing down. The soon-to-launch AITHYRA Institute, a revolutionary research hub for biomedical AI, will be one of the first of its kind in Europe. With Michael Bronstein, DeepMind Professor of AI at the University of Oxford, at the helm, the institute will bring together experts and apply state-of-the-art technology to better understand diseases, speed up diagnoses, and help develop new treatments. Dr Stampfer sees this growth as part of a larger trend. He describes Vienna's life sciences sector as being 'on a qualitative and quantitative growth course', which means there are 'lots of attractive positions available' for international talent. Young pharmacy researchers. Supportive community and funding opportunities Moving to a new country can feel daunting but there is plenty of support for newcomers. The Vienna Business Agency offers free consultations, events and guidance to researchers and entrepreneurs on everything from funding applications to finding a flat. Support is also available at the WWTF, which provides research funding as well as a Dual Career Service to assist researchers and their partners in settling in Vienna. According to Dr Stampfer, researchers are 'pleasantly surprised by our comprehensive support system for international scientists and the efficiency of our funding administration'. LISAvienna, the city's life sciences platform, offers targeted support for biotech and digital health startups, including help with grants, contacts and networking. Vienna is also gaining recognition on the global stage. Researchers are publishing in prestigious journals, while centres such as the Institute of Science and Technology Austria (ISTA), are winning competitive European Research Council grants. 'We also witness an expanding life sciences startup ecosystem, and venture capital funds taking a closer look at what is happening in Vienna,' Dr Stampfer adds. Meanwhile, international recruitment is strong, particularly among early-career scientists. This can be seen in initiatives such as the WWTF's Vienna Research Groups programme. Dr Stampfer says the rising number of young people coming to Vienna 'creates a vibrant research environment with fresh perspectives'. Working in one of Vienna's many welcoming cafés. Life beyond the lab Science isn't the only reason for choosing Wien. The city is regularly crowned one of the most liveable in the world due to its excellent infrastructure, healthcare, cultural scene and green space. Residents enjoy affordable and efficient public transport alongside family-friendly policies like free childcare for young children. Vienna's international connections are another advantage. Thanks to a major airport and fast train links it's easy to travel around Europe or further afield. 'The central European location and rich cultural landscape exceed expectations, even for those with high initial hopes,' says Dr Stampfer. Of course, there is the odd Viennese quirk. 'Researchers might be a little surprised by the playful grumpiness of our local coffee house waiters – and the many urban legends around it,' adds Dr Stampfer. 'But this is something people get used to quickly.' 'Building the future' From Freud's psychoanalysis to Schrödinger's quantum theory, Vienna has long attracted brilliant minds. That tradition has continued with major contributions to fields such as gene editing, attosecond physics and quantum entanglement. Now, new projects in digital medicine and AI-driven health research are opening up even more possibilities. With centres like AITHYRA on the horizon, a flourishing startup scene and a growing international community, Vienna is quickly becoming the top choice for researchers and entrepreneurs looking for a European base. Through the platform ViennaBusiness, the city is now offering expert consultations and other support to international researchers and life-science companies interested in exploring the city. 'It's exciting to see great minds flourish in Vienna,' says Dr Stampfer. 'We are building the future here.'
Yahoo
17-07-2025
- Business
- Yahoo
Veterinary Active Pharmaceutical Ingredients (API) Market Research Report 2025-2034
Growth is driven by rising pet ownership, heightened focus on animal health, and technological advancements in veterinary care. The market is fueled by increased demand for veterinary medications addressing zoonotic diseases and advanced treatment options. Segmented by API type, anti-parasitics lead with significant growth, complemented by chemical-based APIs which dominate due to their cost-efficiency and therapeutic versatility. Companion animal care is thriving, projected to reach USD 10.7 billion by 2034. Regional analysis highlights North America as a key player, propelled by robust pet ownership and strong healthcare infrastructure. Major companies like AMGIS Lifescience, Boehringer Ingelheim, and Vetpharma drive innovation and expansion. Veterinary Active Pharmaceutical Ingredients (API) Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Veterinary Active Pharmaceutical Ingredients (API) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" has been added to Global Veterinary Active Pharmaceutical Ingredients (API) Market was valued at USD 7.9 billion in 2024 and is estimated to grow at a CAGR of 7.4% to reach USD 16 billion by 2034 This steady growth is largely fueled by increasing pet ownership, rising awareness about animal health, and advancements in veterinary technologies. Consumers are becoming more inclined to treat animals with the same level of healthcare they expect for themselves, which has directly impacted the demand for quality veterinary medications. The growing prevalence of zoonotic diseases has also intensified the urgency for reliable treatments, making veterinary APIs more crucial than ever in the development of safe and effective drugs. Veterinary APIs are core ingredients used to formulate medicines that treat, manage, or prevent diseases in animals. These ingredients are essential for both livestock and companion animals, serving a wide range of therapeutic applications. With the increase in global livestock production and pet adoption, there is a consistent need for high-quality APIs that meet regulatory benchmarks such as Good Manufacturing Practices (GMP). APIs are cost-effective due to their compatibility with bulk production, ensuring price efficiency without compromising quality. They also allow pharmaceutical manufacturers to tailor drugs for specific species and dosage forms, including oral, injectable, and feed-based solutions. The flexibility, affordability, and high consistency of APIs make them integral to producing effective veterinary market is segmented by API type into anti-parasitics, anti-infectives, vaccines, biologics, hormones, anti-inflammatories, and other APIs. Among these, anti-parasitics dominated the market with a revenue of USD 2 billion in 2024 and are forecasted to reach USD 4.2 billion by 2034, recording a CAGR of 7.9%. The increasing incidence of parasitic diseases in animals, such as heartworms, fleas, and gastrointestinal infections, is driving the demand for targeted anti-parasitic treatments, which in turn pushes the need for robust and quality APIs in this on synthesis type, the market is categorized into chemical-based APIs, biological APIs, and highly potent APIs (HPAPIs). Chemical-based APIs held the largest share of 58.2% in 2024 due to their cost-efficiency, long shelf life, and ease of mass production. These APIs are widely used in treating a range of conditions like infections and inflammation and serve as the foundational building blocks for many veterinary drugs. Their pharmacological properties make them suitable for combination with other ingredients, enhancing their therapeutic efficacy. Continuous improvements in chemical synthesis technologies are also supporting the increased adoption of these APIs across various veterinary terms of animal type, the market is segmented into livestock animals and companion animals. The companion animals segment is projected to grow at a CAGR of 7.6%, reaching USD 10.7 billion by 2034. This growth is attributed to the increasing trend of pet humanization and the willingness of pet owners to invest in preventive and therapeutic healthcare. Demand for advanced veterinary pharmaceuticals such as biologics, hormones, and anti-inflammatory drugs continues to rise as pet care becomes more specialized and market is further divided by service type into in-house manufacturing and contract outsourcing. In-house manufacturing held the largest market share at 55.3% in 2024 and is projected to reach USD 8.7 billion by 2034. This segment benefits from advantages like enhanced quality assurance, lower production costs, and faster time-to-market for drug development. Companies with in-house API production capabilities are better positioned to manage inventory and adjust to market demands quickly, giving them a competitive edge in the fast-evolving veterinary pharmaceutical North America accounted for the highest revenue of USD 3.1 billion in 2024 and is expected to climb to USD 6 billion by 2034, growing at a CAGR of 7.1%. The region's leadership is reinforced by widespread pet ownership, high awareness of animal health issues, and a strong veterinary healthcare infrastructure. The demand for premium-quality APIs continues to increase as more consumers seek advanced treatments for both pets and livestock, supporting North America's dominant position in the global players actively contributing to the market landscape include AMGIS Lifescience, Abino Pharma, BOC Sciences, Hikal, Huvepharma (Olon), Boehringer Ingelheim, Indukern Group, NGL Fine-Chem, Menadiona, Ofichem Group, Qilu Pharmaceutical, Sequent Scientific, Procyon Life Sciences, SUANFARMA, Vetpharma, and Veyx-Pharma. These companies are focused on strengthening their manufacturing capabilities, expanding their product portfolios, and meeting rising global demand for veterinary APIs. Key Attributes: Report Attribute Details No. of Pages 160 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $7.9 Billion Forecasted Market Value (USD) by 2034 $16 Billion Compound Annual Growth Rate 7.4% Regions Covered Global Comprehensive Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Drivers Rising pet ownership rate Growing initiative and awareness for animal health Growing technological advancements in drug formulations Rising incidence of zoonotic disease Expanding outsourcing services Challenges Stringent regulatory approval High R&D cost Company Profiles Abino Pharma AMGIS Lifescience BOC Sciences. Boehringer Ingelheim Hikal Huvepharma Indukern Group Menadiona NGL Fine-Chem Ofichem Group Procyon Life Sciences Qilu Pharmaceutical Sequent Scientific SUANFARMA Vetpharma Veyx-Pharma For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Veterinary Active Pharmaceutical Ingredients (API) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
